Download PDF

1. Company Snapshot

1.a. Company Description

NEXGEL, Inc.manufactures high water content, electron beam cross-linked, and aqueous polymer hydrogels and gels.Its products are used for wound care, medical diagnostics, transdermal drug delivery, and cosmetics.


The company was formerly known as AquaMed Technologies, Inc.and changed its name to NEXGEL, Inc.in November 2019.


NEXGEL, Inc.was founded in 1997 and is based in Langhorne, Pennsylvania.

Show Full description

1.b. Last Insights on NXGL

Negative drivers behind NEXGEL, Inc.'s recent performance include a decline in revenue growth momentum. The company's Q1 2025 earnings call highlighted a 181% year-over-year increase in revenue, but this growth rate is expected to decelerate. Additionally, the company's guidance for Q2 2025 was below analyst expectations, indicating a potential slowdown in revenue expansion. Furthermore, the absence of any significant new product launches or strategic acquisitions in the recent quarter may have contributed to the decline in investor sentiment.

1.c. Company Highlights

2. Transcript Summary

Unfortunately this company is not part of our coverage yet. But as part of your subscription plan you can request it by clicking just below and we'll process.

3. NewsRoom

Card image cap

NEXGEL, Inc. (NXGL) Q3 2025 Earnings Call Transcript

Nov -12

Card image cap

NEXGEL Reports Third Quarter 2025 Financial Results

Nov -11

Card image cap

NEXGEL, Inc. (NXGL) Q2 2025 Earnings Call Transcript

Aug -12

Card image cap

NEXGEL Appoints Chief Accounting Officer of Shutterstock, Steve Ciardiello, CPA, to its Board of Directors

Aug -05

Card image cap

NEXGEL Announces $950,000 Registered Direct Offering and Concurrent Private Placement

Aug -01

Card image cap

NEXGEL and STADA AG Announce Expansion of Partnership for North America

Jul -14

Card image cap

NEXGEL, Inc. (NXGL) Q1 2025 Earnings Call Transcript

May -14

Card image cap

NEXGEL, Inc. (NXGL) Q4 2024 Earnings Call Transcript

Mar -24

4. Business Breakdown

4.a. Revenues by Country

4.b. Revenues by Segment

5. Expected revenues mid-term growth (11.30%)

6. Segments

Nexgel

Expected Growth: None%

None

CGN JV

Expected Growth: None%

None

7. Detailed Products

Nexgel Wound Care

A line of hydrogel-based wound care products designed to promote wound healing, reduce pain, and improve patient outcomes.

Nexgel Post-Operative Care

A range of products designed to reduce pain, swelling, and bruising after surgery, promoting faster recovery and reduced scarring.

Nexgel Orthopedic Support

A line of orthopedic support products, including braces, wraps, and sleeves, designed to provide stability, support, and pain relief.

Nexgel Pain Relief

A range of topical pain relief products, including creams, gels, and sprays, designed to provide fast and effective pain relief.

Nexgel Skincare

A line of skincare products, including moisturizers, cleansers, and sunscreens, designed to promote healthy skin and prevent skin damage.

8. NEXGEL, Inc.'s Porter Forces

Forces Ranking

Threat Of Substitutes

NEXGEL, Inc. has a low threat of substitutes due to its unique gel-based products that are not easily replaceable by other products.

Bargaining Power Of Customers

NEXGEL, Inc. has a medium bargaining power of customers due to the presence of a few large customers, but the company's products are still differentiated and valued by customers.

Bargaining Power Of Suppliers

NEXGEL, Inc. has a low bargaining power of suppliers due to its ability to source raw materials from multiple suppliers and its strong relationships with suppliers.

Threat Of New Entrants

NEXGEL, Inc. has a high threat of new entrants due to the relatively low barriers to entry in the gel-based products market and the attractiveness of the market to new entrants.

Intensity Of Rivalry

NEXGEL, Inc. operates in a moderately competitive market with a few established players, but the company's differentiated products and strong brand recognition help to mitigate the intensity of rivalry.

9. SWOT Analysis

10. Capital Structure

10.a. Balance Sheet

10.b. Weighted Average Cost of capital

Value
Debt Weight 18.57%
Debt Cost 3.95%
Equity Weight 81.43%
Equity Cost 7.91%
WACC 7.17%
Leverage 22.80%

11. Quality Control: NEXGEL, Inc. passed 4 out of 9 key points

12.a Historical Valuation

12.b Price/Earnings Ratio

12.c Margin Valuation

12.d Peers Valuation

Peers Group Analysis

Stock-Card
InfuSystem Holdings

A-Score: 4.6/10

Value: 4.6

Growth: 5.7

Quality: 5.7

Yield: 0.0

Momentum: 8.5

Volatility: 3.0

1-Year Total Return ->

Stock-Card
Atrion

A-Score: 3.5/10

Value: 3.5

Growth: 3.0

Quality: 6.2

Yield: 1.0

Momentum: 5.0

Volatility: 2.0

1-Year Total Return ->

Stock-Card
NEXGEL

A-Score: 3.3/10

Value: 7.4

Growth: 4.9

Quality: 4.2

Yield: 0.0

Momentum: 1.5

Volatility: 1.7

1-Year Total Return ->

Stock-Card
STAAR Surgical

A-Score: 3.2/10

Value: 8.0

Growth: 4.1

Quality: 3.8

Yield: 0.0

Momentum: 1.5

Volatility: 2.0

1-Year Total Return ->

Stock-Card
Femasys

A-Score: 2.7/10

Value: 6.0

Growth: 2.8

Quality: 3.1

Yield: 0.0

Momentum: 4.0

Volatility: 0.3

1-Year Total Return ->

Stock-Card
Harvard Bioscience

A-Score: 2.2/10

Value: 9.2

Growth: 1.1

Quality: 2.6

Yield: 0.0

Momentum: 0.0

Volatility: 0.0

1-Year Total Return ->

Peers Metrics

12.e Scoring Insights

12.f DCF BETA

Parameters

Short Term Growth

Short term Time

Long-Term Growth

WACC

Target Price

1.58$

Current Price

1.58$

Potential

-0.00%

Expected Cash-Flows